FrancophonIA/ELRC3.0 huggingface dataset:
English: Concomitant prednisone use (40 mg/day for the first 14 days of Viramune administration) has been shown not to decrease the incidence of nevirapine-associated rash, and may be associated with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy.
Slovenian: Pokazalo se je, da sočasna uporaba prednizona (40 mg na dan prvih 14 dni zdravljenja z zdravilom Viramune) ne zmanjša pogostnosti izpuščaja, ki ga povzroča nevirapin, možno pa je, da je povezana s povečano pogostnostjo in resnostjo izpuščaja prvih 6 tednov zdravljenja z nevirapinom.
English: The dose is one 200 mg tablet per day for the first 14 days of treatment (“lead-in” period).
Slovenian: Odmerek je ena tableta po 200 mg na dan prvih 14 dni zdravljenja (”uvajalno” obdobje).
English: Hormonal methods of birth control other than Depo-medroxyprogesterone acetate (DMPA) should not be used as the sole method of contraception in women taking Viramune, since nevirapine might lower the plasma concentrations of these medicinal products.
Slovenian: Ženske, ki jemljejo zdravilo Viramune, ne smejo uporabljati hormonskih metod za preprečevanje zanositve, razen depo-medroksiprogesteron acetata (DMPA), kot edino metodo kontracepcije, ker lahko nevirapin zmanjša koncentracijo teh zdravil v plazmi.
English: When Viramune prolonged-release was dosed with a high fat meal, the nevirapine AUC0-24,ss and Cmin,ss were approximately 94 % and 98 %, respectively, of the AUC0-24,ss and Cmin,ss measured when patients were dosed with Viramune immediate-release tablets.
Slovenian: Če so zdravilo Viramune s podaljšanim sproščanjem dajali ob obroku z veliko vsebnostjo maščob, sta bili nevirapinovi AUC0-24,ss in Cmin,ss približno 94 % oziroma 98 % AUC0-24,ss in Cmin,ss, izmerjenih po jemanju zdravila Viramune tablete s takojšnjim sproščanjem.
English: Tipranavir/ritonavir 500/200 mg BID
Slovenian: Tipranavir/ritonavir 500/200 mg 2-krat na dan
English: Therefore coadministration would likely result in altered plasma levels of cobicistat and Viramune.
Slovenian: Pri sočasnem dajanju bi se verjetno spremenile ravni kobicistata in zdravila Viramune v plazmi.
English: Try not to miss a dose.
Slovenian: Pazite, da odmerka ne bi pozabili vzeti.
English: The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe weakness of the immune system and higher body mass index may be some of the many risk factors for developing this disease.
Slovenian: Nekateri od številnih dejavnikov tveganja za pojav te bolezni so lahko trajanje kombiniranega protiretrovirusnega zdravljenja, uporaba kortikosteroidov, uživanje alkohola, hudo zmanjšanje imunskega odziva in višji indeks telesne mase.
English: Otherwise patients with CLcr  20 ml/min do not require an adjustment in nevirapine dosing.
Slovenian: Bolnikom s CLcr  20 ml/min odmerka nevirapina sicer ni treba prilagajati.
English: - The other ingredients are: microcrystalline cellulose, lactose (as monohydrate), povidone K25, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate.
Slovenian: - Druge sestavine zdravila so: mikrokristalna celuloza laktoza (v obliki monohidrata) povidon K25 natrijev karboksimetilškrob koloidni silicijev dioksid in magnezijev stearat.
English: If a patient is already taking St. John‘s Wort check nevirapine and if possible viral levels and stop St. John‘s Wort.
Slovenian: Če bolnik že jemlje šentjanževko, je treba preveriti raven nevirapina in po možnosti virusa, bolnik pa naj jo preneha jemati.
English: Viramune 200 mg Tablets
Slovenian: Viramune 200 mg tablete
English: Only a small fraction (< 5%) of the radioactivity in urine (representing < 3 % of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Slovenian: Samo majhna frakcija (< 5 %) radioaktivnosti v seču (< 3 % skupnega odmerka) je bila iz matične spojine.
English: It is not recommended to coadminister efavirenz and Viramune (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1 Viramune immediate-release formulations).
Slovenian: Sočasnega dajanja efavirenza in zdravila Viramune ne priporočamo (glejte poglavje 4.4), ker se toksični učinki seštevajo in v primerjavi z dajanjem enega ali drugega NNRTI samega ni dodatne koristi (za rezultate študije 2NN glejte poglavje 5.1 zdravila Viramune s podaljšanim sproščanjem).
English: The pharmacokinetics of Viramune prolonged-release has also been studied in a multiple dose pharmacokinetics study (study 1100.1489) in 24 HIV-1 infected patients who switched from chronic Viramune immediate-release therapy to Viramune prolonged-release.
Slovenian: Farmakokinetiko zdravila Viramune s podaljšanim sproščanjem so proučevali tudi v študiji o večkratnih odmerkih (1100.1489), v katerih je sodelovalo 24 s HIV-1 okuženih bolnikov, ki so jim kronično zdravljenje z zdravilom Viramune s takojšnjim sproščanjem zamenjali z zdravilom Viramune s podaljšanim sproščanjem.
English: Viramune may be dosed in paediatric patients either by body surface area (BSA) or by body weight as follows: By BSA using the Mosteller formula the recommended oral dose for paediatric patients of all ages is 150 mg/m2 once daily for two weeks followed by 150 mg/m2 twice daily thereafter.
Slovenian: Zdravilo Viramune otrokom odmerjamo glede na telesno površino ali telesno maso na naslednji način: Priporočeni peroralni odmerek za otroke vseh starosti, določen na podlagi telesne površine po Mostellerjevi formuli je 150 mg/m2 enkrat na dan, dva tedna, nato sledi odmerjanje 150 mg/m2 dvakrat na dan.
English: Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing regimen using the two week lead-in period of Viramune immediate-release.
Slovenian: Bolniki, ki prekinejo jemanje nevirapina za več kot 7 dni, lahko nadaljujejo jemanje po priporočeni shemi odmerjanja in po dvotedenskem uvajalnem obdobju z zdravilom Viramune s takojšnjim sproščanjem.
English: Nevirapine AUC  1.26
Slovenian: AUC nevirapina  1,26
English: The tablets shall be taken with liquid, and should not be crushed or chewed.
Slovenian: Tablete je treba jemati s tekočino, ne sme se jih drobiti ali žvečiti.
English: In a single dose pharmacokinetic study of 200 mg Viramune immediate-release tabletsof in HIVnegative patients with mild and moderate hepatic impairment (Child-Pugh A, n=6; Child-Pugh B,
Slovenian: Farmakokinetično študijo z enkratnim 200 mg odmerkom zdravila Viramune s takojšnim sproščanjem so izvedli pri bolnikih z negativnim izvidom za HIV in z blago ali zmerno jetrno okvaro (Child-Pugh A, n = 6; Child-Pugh B, n = 4).
English: Nevirapine AUC  0.42
Slovenian: AUC nevirapina  0,42
English: Fertility In reproductive toxicology studies, evidence of impaired fertility was seen in rats.
Slovenian: Plodnost V raziskavah o vplivu na sposobnost razmnoževanja so pri podganah zasledili manjšo plodnost.
English: Excipients: includes sucrose, sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate (see leaflet for further information)
Slovenian: Pomožne snovi: vključujejo saharozo, sorbitol, metilparahidroksibenzoat, propilparahidroksibenzoat (za podrobne podatke glejte priloženo navodilo).
English: Nevirapine concentrations not measured, no effect is expected.
Slovenian: Nevirapinovih koncentracij niso merili.
English: Hepatic impairment: A steady state study comparing 46 patients with mild (n=17: Ishak Score 1-2), moderate (n=20; Ishak Score 3-4), or severe (n=9; Ishak Score 5-6, Child-Pugh A in 8 pts., for 1 Child-Pugh score not applicable) liver fibrosis as a measure of hepatic impairment was conducted.
Slovenian: Jetrna okvara: Opravili so študijo stanja dinamičnega ravnovesja, v kateri je sodelovalo 46 bolnikov, ki so imeli: blago (n = 17: ocena 1 do 2 po Ishaku), zmerno (n = 20; ocena 3 do 4 po Ishaku) ali hudo (n = 9; ocena 5 do 6 po Ishaku, Child-Pugh A pri 8 bolnikih, pri 1 bolniku ocene po ChildPughu niso uporabili) jetrno fibrozo, ki je veljala kot merilo za jetrno okvaro.
English: If clinical hepatitis occurs, characterised by anorexia, nausea, vomiting, icterus AND laboratory findings (such as moderate or severe liver function test abnormalities (excluding GGT)), nevirapine must be permanently stopped.
Slovenian: Če se pojavi klinična oblika hepatitisa z anoreksijo, slabostjo, bruhanjem in zlatenico IN nenormalnimi laboratorijskimi izvidi (zmernimi ali hudimi spremembami v jetrni funkciji (razen GGT)), moramo nevirapin trajno ukiniti.
English: Female gender and higher CD4 counts (>250/mm
Slovenian: Pri ženskah in bolnikih z večjim številom celic CD4 (> 250/mm
English: For smaller children an oral suspension liquid form is available.
Slovenian: Za manjše otroke je na voljo peroralna suspenzija.
English: Nevirapine Cmin  0.32
Slovenian: Cmin nevirapina  0,32
English: If rash occurs and you also feel sick, you must stop treatment and visit your doctor immediately.
Slovenian: Če kadarkoli med zdravljenjem opazite izpuščaj in vam je hkrati slabo, morate zdravilo prenehati jemati in nemudoma obiskati zdravnika.
English: Furthermore, an immediate-release oral suspension dosage form is available for all age groups for a twice daily administration (please refer to the respective Summary of Product Characteristics).
Slovenian: Poleg tega je za otroke vseh starostnih skupin na voljo še peroralna suspenzija s takojšnjim sproščanjem, ki jo jemljejo dvakrat na dan (glejte Povzetek glavnih značilnosti zdravila za to obliko zdravila).
English: - The active substance is nevirapine.
Slovenian: - Učinkovina je nevirapin.
English: If you develop severe liver, skin or hypersensitivity reactions whilst taking Viramune, NEVER TAKE VIRAMUNE again without referring to your doctor.
Slovenian: Če se pri vas med jemanjem zdravila Viramune razvijejo hude jetrne, kožne ali preobčutljivostne reakcije, NE NADALJUJTE z jemanjem zdravila, ne da bi se prej posvetovali z zdravnikom.
English: Very common (may affect more than 1 in 10 people): - rash
Slovenian: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): - izpuščaj.
English: However, patients should be advised that they may experience adverse reactions such as fatigue during treatment with nevirapine.
Slovenian: Bolnikom je treba povedati, da se med zdravljenjem z nevirapinom lahko pojavijo neželeni učinki, na primer utrujenost.
English: Viramune is also available in liquid form as an oral suspension.
Slovenian: Zdravilo Viramune je na voljo tudi v tekoči obliki kot peroralna suspenzija.
English: Renal impairment: The single-dose pharmacokinetics of nevirapine immediate-release has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
Slovenian: Ledvična okvara: Farmakokinetiko nevirapina s takojšnim sproščanjem so po enkratnem odmerku primerjali pri 23 bolnikih z blago (50  CLcr < 80 ml/min), zmerno (30  CLcr < 50 ml/min) ali hudo motnjo ledvične funkcije (CLcr < 30 ml/min), ledvično okvaro ali ledvično boleznijo v končni fazi, ki je zahtevala dializo, ter pri 8 osebah z normalno ledvično funkcijo (CLcr > 80 ml/min).
English: Table 2: Maintenance phase of Viramune prolonged-release
Slovenian: Preglednica 2: Obdobje vzdrževalnega zdravljenja z zdravilom Viramune s podaljšanim sproščanjem
English: If co-administered with Viramune, an adjustment in the telaprevir dose should be considered.
Slovenian: Pri sočasnem dajanju z zdravilom Viramune je treba presoditi o prilagoditvi odmerka telaprevirja.
English: NAME OF THE MEDICINAL PRODUCT Viramune 50 mg/5 ml oral suspension
Slovenian: IME ZDRAVILA Viramune 50 mg/5 ml peroralna suspenzija
English: Renal impairment: The single-dose pharmacokinetics of nevirapine has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
Slovenian: Ledvična okvara: Farmakokinetiko nevirapina so po enkratnem odmerku primerjali pri 23 bolnikih z blago (50  CLcr < 80 ml/min), zmerno (30  CLcr < 50 ml/min) ali hudo motnjo ledvične funkcije (CLcr < 30 ml/min), ledvično okvaro ali ledvično boleznijo v končni fazi, ki je zahtevala dializo, ter pri 8 osebah z normalno ledvično funkcijo (CLcr > 80 ml/min).
English: Elderly Nevirapine has not been specifically investigated in patients over the age of 65.
Slovenian: Starejši Nevirapina niso posebej preskušali pri bolnikih nad 65 let.
English: The side effects described below have been experienced by patients given Viramune 200 mg tablets during the 14 day lead-in phase:
Slovenian: Našteti neželeni učinki so se pojavili pri bolnikih, ki so jemali zdravilo Viramune 200 mg tablete med 14-dnevnim uvajalnim obdobjem:
English: At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA < 50 copies/ml.
Slovenian: Štiriindvajset tednov po naključni uvrstitvi v študijo TRANxITION je bil pri 92,6 % bolnikov, ki so dvakrat na dan jemali po 200 mg zdravila Viramune s takojšnjim sproščanjem, in 93,6 % bolnikov, ki so enkrat na dan jemali po 400 mg zdravila Viramune s podaljšanim sproščanjem, HIV-1 RNK še vedno manj kot 50 kopij/ml.
English: The greatest risk of hepatic and skin reactions occurs in the first 6 weeks of therapy.
Slovenian: Nevarnost jetrnih in kožnih reakcij je največja prvih 6 tednov zdravljenja.
English: In study 1100.1526 (TRANxITION) patients on Viramune 200 mg immediate-release twice daily treatment for at least 18 weeks were randomised to either receive Viramune 400 mg prolonged-release once daily (n=295) or remain on their Viramune immediate-release treatment (n=148).
Slovenian: V študiji 1100.1526 (TRANxITION) so bolnike, ki so se najmanj 18 tednov zdravili z zdravilom Viramune s takojšnjim sproščanjem po 200 mg dvakrat na dan, naključno razvrstili v skupino zdravljeno z zdravilom Viramune s podaljšanim sproščanjem po 400 mg enkrat na dan (n = 295) ali v nadaljevanje zdravljenja z zdravilom Viramune s takojšnjim sproščanjem (n = 148).
English: If you are uncertain please be sure to ask your child's doctor.
Slovenian: Če ste negotovi, se posvetujte z otrokovim zdravnikom.
English: However, patients with ESRD requiring dialysis exhibited a 43.5 % reduction in nevirapine AUC over a one-week exposure period.
Slovenian: Pri bolnikih s končno fazo ledvične bolezni, ki so se morali zdraviti z dializo, pa se je AUC nevirapina v enem tednu jemanja zmanjšala za 43,5 %.
English: Patients with CLcr  20 ml/min do not require a dose adjustment, see section 5.2.
Slovenian: Bolnikom s CLcr ≥ 20 ml/min odmerka ni treba prilagajati; glejte poglavje 5.2.
English: Viramune oral suspension contains 162 mg sorbitol per ml.
Slovenian: Peroralna suspenzija Viramune vsebuje 162 mg sorbitola v enem mililitru.
English: Viramune is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Slovenian: Zdravilo Viramune je kontraindicirano za bolnike s hudo jetrno okvaro (Child-Pugh C) (glejte poglavje 4.3).
English: 1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
Slovenian: 1216 bolnikov, ki se še niso zdravili s protiretrovirusnimi zdravili in so imeli izhodiščno plazemsko koncentracijo HIV-1 RNA > 5000 kopij/ml so razvrstili v skupine zdravljenje z zdravilom Viramune po 400 mg enkrat na dan ali po 200 mg dvakrat na dan, efavirenzem po 600 mg enkrat na dan ali zdravilom Viramune (400 mg) in efavirenzem (800 mg) enkrat na dan, skupaj s stavudinom in lamivudinom, ki je trajalo 48 tednov.
English: Viramune 200 mg tablets, following the dosing schedule described above, are suitable for larger children, particularly adolescents, below the age of 16 who weigh more than 50 kg or whose body surface area is above 1.25 m2 according to the Mosteller formula.
Slovenian: Zdravilo Viramune 200 mg tablete je po zgoraj opisani shemi odmerjanja primerne za večje otroke, zlasti mladostnike, ki so mlajši od 16 let in težki več kot 50 kg ali katerih telesna površina presega 1,25 m2 po Mostellerjevi formuli.
English: Baseline Plasma HIV-1 RNA (log10 copies/ml) - Mean (SD)
Slovenian: Izhodiščna raven HIV-1 RNK v plazmi (log10 kopiu/ml) - srednja vrednost (SD)
English: The following adverse reactions which may be causally related to the administration of Viramune prolonged-release tablets have been reported.
Slovenian: Poročila navajajo naslednje neželene učinke, ki so lahko vzročno povezani z dajanjem zdravila Viramune s podaljšanim sproščanjem.
English: ANTI-INFECTIVES ANTIRETROVIRALS NRTIs
Slovenian: UČINKOVINE ZA ZDRAVLJENJE INFEKCIJ Protiretrovirusna zdravila NRTI (nukleozidni zaviralci reverzne transkriptaze) Didanozin
English: MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH Binger Strasse 173
Slovenian: IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM Boehringer Ingelheim International GmbH Binger Strasse 173
English: Yellow, round and biconvex prolonged-release tablets.
Slovenian: Rumene, okrogle, bikonveksne tablete s podaljšanim sproščanjem.
English: No drug-drug interaction study of telaprevir with nevirapine has been conducted, however, interaction studies of telaprevir with an NNRTI with a similar metabolic pathway as nevirapine demonstrated reduced levels of both.
Slovenian: Raziskav medsebojnega delovanja telaprevirja in nevirapina niso izvedli, toda v raziskavah medsebojnega delovanja telaprevirja in NNRTI s podobno presnovno potjo, kot jo ima nevirapin, se je raven obeh znižala.
English: The absorption of nevirapine is not affected by food, antacids or medicinal products which are formulated with an alkaline buffering agent.
Slovenian: Hrana, antacidi ali zdravila, ki so izdelana z alkalnim puferskim sredstvom, ne vplivajo na absorpcijo nevirapina.
English: Viramune administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Slovenian: Dajanje večjih od priporočenih odmerkov zdravila Viramune lahko poveča pogostnost in resnost kožnih reakcij, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
English: Viramune 100 mg prolonged-release tablets are yellow, round and biconvex.
Slovenian: Zdravilo Viramune 100 mg tablete s podaljšanim sproščanjem so rumene, okrogle in na obeh straneh izbočene.
English: Rare (may affect up to 1 in 1000 people): - sudden and intense inflammation of the liver (fulminant hepatitis) - drug reaction with systemic symptoms (drug reaction with eosinophilia and systemic symptoms)
Slovenian: Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): - nenadno in močno vnetje jeter (fulminantni hepatitis) - medikamentna reakcija s sistemskimi simptomi (medikamentna reakcija z eozinofilijo in sistemskimi simptomi).
English: If you are undergoing kidney dialysis, your doctor may consider a dose adjustment of Viramune.
Slovenian: Če se zdravite z dializo, bo zdravnik presodil o potrebni prilagoditvi odmerka zdravila Viramune.
English: There are toxicities that require interruption of Viramune therapy (see section 4.4).
Slovenian: Pojavijo se lahko toksični učinki, zaradi katerih je potrebno prekiniti zdravljenje z zdravilom Viramune (glejte poglavje 4.4).
English: However, in some patients a rash, which appears as a blistering skin reaction, can be severe or life-threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis) and deaths have been recorded.
Slovenian: Pri nekaterih bolnikih pa je lahko izpuščaj, ki se pojavi kot mehurjasta kožna reakcija, hud ali življenjsko nevaren (Stevens-Johnsonov sindrom in toksična epidermalna nekroliza); zabeležili so že tudi smrtne izide.
English: The observed mutations at failure were those expected with a nevirapine-based regimen.
Slovenian: Mutacije, ki so jih zasledili med neuspešnim zdravljenjem, so pri nevirapinu pričakovane.
English: Viramune prolonged-release n=505
Slovenian: Zdravilo Viramune s podaljšanim sproščanjem n = 505
English: In the multinational 2NN study, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females.
Slovenian: V večnacionalni raziskavi 2NN so izvedli populacijsko farmakokinetično podraziskavi pri 1077 bolnikih, v kateri je sodelovalo 391 žensk.
English: These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity reactions characterised by rash, constitutional findings and visceral involvement.
Slovenian: Gre za primere Stevens-Johnsonovega sindroma, toksične epidermalne nekrolize in preobčutljivostnih reakcij, za katere so bili značilni izpuščaj, splošni simptomi in prizadetost visceralnih organov.
English: Viramune contains lactose and sodium
Slovenian: Zdravilo Viramune vsebuje laktozo in natrij
English: Nevirapine administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Slovenian: Dajanje večjih od priporočenih odmerkov nevirapina lahko poveča pogostnost in resnost kožnih reakcij, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
English: Weight Range (kg) for patients  8 years of age
Slovenian: Razpon telesne mase (kg) bolnikov, starih  8 let
English: Based on clinical study experience of 361 paediatric patients the majority of which received combination treatment with ZDV or/and ddI, the most frequently reported adverse events related to nevirapine were similar to those observed in adults.
Slovenian: Na podlagi izkušenj iz kliničnih študij, v katera je bilo vključenih 361 otrok, od katerih je večina prejemala kombinirano zdravljenje z ZDV ali/in ddI, so najpogostejši neželeni dogodki, ki so povezani z nevirapinom, podobni kot pri odraslih.
English: Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Sorbitol
Slovenian: 6.1 Seznam pomožnih snovi karbomer metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) sorbitol saharoza polisorbat 80 natrijev hidroksid (za uravnavo pH) prečiščena voda
English: Viramune is indicated for the treatment of HIV-1 infected adults, adolescents, and children of any age.
Slovenian: Zdravilo Viramune je indicirano za zdravljenje s HIV-1 okuženih odraslih, mladostnikov in otrok vseh starosti.
English: These events are commonly associated with other antiretroviral agents and may be expected to occur when Viramune is used in combination with other agents; however, it is unlikely that these events are due to treatment with Viramune.
Slovenian: Ta stanja so večinoma povezana z drugimi protivirusnimi zdravili in se lahko pojavijo, kadar jemljete zdravilo Viramune v kombinaciji z drugimi zdravili, ni pa verjetno, da jih povzroča samo zdravljenje z zdravilom Viramune.
English: Dose adjustment of Viramune is not required when co-administered with lopinavir.
Slovenian: Odmerka zdravila Viramune ni treba prilagoditi, če ga dajemo hkrati z lopinavirjem.
English: Methadone AUC  0.40 (0.31 - 0.51) Methadone Cmin ND Methadone Cmax  0.58 (0.50 - 0.67)
Slovenian: AUC metadona  0,40 (0,31-0,51) Cmin metadona ND Cmax metadona  0,58 (0,50-0,67)
English: The prolonged-release tablet should not be divided.
Slovenian: Tablet s podaljšanim sproščanjem ne smete deliti.
English: Blood and lymphatic system disorders Uncommon granulocytopenia Rare anaemia
Slovenian: Bolezni krvi in limfatičnega sistema občasni granulocitopenija redki anemija